drugset / Trial / NCT00737633
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how safe VI-0521 is over an extended period of time. All subjects eligible to enroll into this study will receive study drug.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-03
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Phentermine | Small molecule | 15 mg | Oral |
| Subject | Topiramate | Small molecule | 92 mg | Oral |